AKR1C3-Dependent KARS Inhibitor Crystal Form for Polymorph Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need to provide a solid state form of 6′-fluoro-N-(4-fluorobenzyl)-4′-oxo-3′,4′-dihydro-1′H-spiro[piperidine-4,2′-quinoline]-1-carboxamide that possesses physicochemical properties allowing for a reliable production of a safe and efficacious drug product, as existing technologies do not account for the potential polymorphism of this compound, which can affect solubility, formulation properties, and bioavailability.
Innovation Solution
The development of a crystalline form, specifically Form A, of 6′-fluoro-N-(4-fluorobenzyl)-4′-oxo-3′,4′-dihydro-1′H-spiro[piperidine-4,2′-quinoline]-1-carboxamide, which is anhydrous and substantially pure, along with processes for its production, including reaction and isolation methods, to ensure consistent drug quality.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If a compound can crystallize in multiple crystalline forms (polymorphism), then the drug's solubility, formulation properties, and bioavailability may be improved, but the manufacturing process becomes more complex and unpredictable due to unknown crystalline forms during manufacture
Solution Approach 1:
The patent identifies and characterizes multiple crystalline forms of the compound before manufacturing, determining which form(s) to produce and how to control the crystallization process. This preliminary identification and control strategy prevents unexpected polymorphic outcomes during manufacture while maintaining the benefits of multiple forms for improved solubility and bioavailability.
2Reliability
If different crystalline forms are produced to maximize desired properties like solubility and bioavailability, then drug efficacy is improved, but the reliability of consistent drug quality becomes challenging due to polymorphic variability
Solution Approach 1:
The patent employs specific crystallization parameters (temperature, solvent composition, pH, rate of addition) to control and reproduce the formation of desired crystalline forms. By optimizing these parameters, the process achieves reliable and consistent production of specific polymorphic forms while maintaining the ability to access multiple forms for different formulation requirements.
3Reliability
If unknown crystalline forms occur during manufacture, then production reliability is compromised, but predicting which forms will form is currently not possible
Solution Approach 1:
The patent implements monitoring and characterization techniques during the crystallization process to detect which crystalline forms are forming. This feedback information is used to adjust process parameters in real-time or guide subsequent batch production, ensuring reliable and predictable crystalline form outcomes while maintaining production efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline Form A provides a stable and bioavailable form of the drug, suitable for treating various cancers by inhibiting AKR1C3 dependent KARS, with improved solubility and formulation properties, ensuring reliable drug production and efficacy.
Implementation Method 1
Crystalline forms occur where the same composition of matter crystallizes in a different lattice arrangement resulting in different thermodynamic properties and stabilities specific to the particular crystalline form
Data Source
AI summary
This application relates to crystalline forms of an inhibitor of AKR1C3 dependent KARS.